Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD (ACTIVATE)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in Subjects With Parkinson's Disease With a Pathogenic Variant in the Glucocerebrosidase (GBA1) Gene
Sponsor: Bial R&D Investments, S.A.
A PHASE2 clinical study on Parkinson's Disease, this trial is ongoing. The trial is conducted by Bial R&D Investments, S.A. and has accumulated 10 data snapshots since 2023. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
10 versions recorded-
Jan 2026 — Present [monthly]
Active Not Recruiting PHASE2
-
Sep 2025 — Jan 2026 [monthly]
Active Not Recruiting PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE2
▶ Show 5 earlier versions
-
Apr 2024 — Jun 2024 [monthly]
Recruiting PHASE2
-
Dec 2023 — Apr 2024 [monthly]
Recruiting PHASE2
-
Nov 2023 — Dec 2023 [monthly]
Recruiting PHASE2
-
Aug 2023 — Nov 2023 [monthly]
Recruiting PHASE2
-
May 2023 — Aug 2023 [monthly]
Recruiting PHASE2
First recorded
Mar 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bial R&D Investments, S.A.
For direct contact, visit the study record on ClinicalTrials.gov .